Short answer
Immunovant, Inc. (IMVT) filed its Q4 2025 10-Q quarterly report on Feb 6, 2026 for the quarter ended Dec 31, 2025.
Q4 2025 key financials · XBRL
- Net income
- −$111M
- +0.4% YoY · +12.5% QoQ
- EPS (diluted)
- −$0.61
- +19.7% YoY · +15.3% QoQ
Source: XBRL data from the Immunovant, Inc. (IMVT) Q4 2025 10-Q on SEC EDGAR. USD.
Immunovant, Inc. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Potential HanAll Agreement dispute triggered by ongoing rights return discussions for batoclimab
- Updated risk: Clinical trial timing for IMVT-1402 now delayed, with first top-line data expected in 2027 vs prior undefined timeline
- Regulatory risk: Possible regulatory clinical holds from FDA due to new anti-FcRn safety signals or protocol deficiencies
- Operational risk: Dependence on CROs and clinical sites with risk of slowed patient enrollment impacting near-term trial completion
- Financial risk: Complex international tax structure with risk of transfer pricing adjustments raising consolidated tax liability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunovant, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.